The company had $21.4 million in revenues, up 89 percent from last year's $11.3 million during the same quarter. Most of this increase resulted from sales of reagents and disposables, which increased almost fourfold.
Research and developments costs climbed to $4.5 million from 3.9 million during the year-ago period.
Cepheid reported a net loss of $3.6 million, or $.09 per share, similar to last year's $3.7 million, or $.09 per share, for the same quarter.
As of June 30, Cepheid had $18.4 million in cash and cash equivalents, and $34 million in marketable securities.